Skip to main content
Clinical Trials/IRCT138710101525N1
IRCT138710101525N1
Completed
Phase 3

Incidence of clinical sign and symptom of acute ischemia and vascular complication with Enoxaparin during stenting in comparison with heparin

Vice-chanceller for Research Affairs, Shiraz University of Medical Sciences0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Vice-chanceller for Research Affairs, Shiraz University of Medical Sciences
Enrollment
200
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice-chanceller for Research Affairs, Shiraz University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients with atherosclerotic coronary artery disease (chronic stable angina or acute coronary syndromes) were included if they were candidate for PCI as a result of uncontrolled anginal pain, unresponsive to the maximum dose of nitrates or incidence of adverse drug reactions in which it was impossible to continue medical treatment, Patients with clinical sign of heart failure and ischemic involvement of a relatively large segment of myocardium
  • Exclusion criteria: Age 75 years or older, presence of renal failure defined as creatinine clearance of 30 ml/min and over,creatinine\=2\.5 mg/dl in male and creatinine\=2\.0 mg/dl in female participants, use of bare\-metal stents, presence of primary PCI, receiving heparin or LMWH before randomization, unacceptable prothrombin time (PT) or platelet count, presence of platelet functional disorders or coagulopathies, or hypercoagulopathy syndromes.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials